REFERENCES
- Garrity JA, Bahn RS. Pathogenesis of Graves ophthalmopathy: Implications for prediction, prevention, and treatment. Am J Ophthalmol. 2006;142:147–153.
- Bartalena L, Pinchera A, Marcocci C. Management of Graves’ ophthalmopathy: Reality and perspectives. Endocr Rev. 2000;21:168–199.
- Salvi M, Zhang ZG, Haegert D, et al. Patients with endocrine ophthalmopathy not associated with overt thyroid disease have multiple thyroid immunological abnormalities. J Clin Endocrinol Metab. 1990;70:89–94.
- Bothun ED, Scheurer RA, Harrison AR, et al. Update on thyroid eye disease and management. Clin Ophthalmol. 2009;3:545–551.
- Prabhakar BS, Bahn RS, Smith TJ. Current perspective on the pathogenesis of Graves’ disease and ophthalmopathy. Endocr Rev. 2003;24:802–835.
- Bartley GB, Fatourechi V, Kadrmas EF, et al. Long-term follow-up of Graves ophthalmopathy in an incidence cohort. Ophthalmology. 1996;103:958–962.
- Nowak M, Marek B, Kos-Kudla B, et al. Tear film profile in patients with active thyroid orbitopathy. Klin Oczna. 2005;107:479–482.
- Eckstein AK, Finkenrath A, Heilingenhaus A, et al. Dry eye syndrome in thyroid-associated ophthalmopathy: Lacrimal expression of TSH receptor suggests involvement of TSHR-specific autoantibodies. Acta Ophthalmol Scand. 2004;82:291–297.
- Gilbard JP, Farris Rl. Ocular surface drying and tear film osmolarity in thyroid eye disease. Achta Ophthalmol (Copengh). 1983;61:108–116.
- İskeleli G, Karakoç Y, Abdula A. Tear film osmolarity in patients with thyroid ophthalmopathy. Jpn J Ophthalmol. 2008;52:323–326.
- Schiffman RM, Christianson MD, Jacobsen G, et al. Reliability and validity of the Ocular Surface Disease Index. Arch Ophthalmol. 2000;118:615–621.
- Nelson JD. Impression cytology. Cornea. 1988;7:71–81.
- Nelson JD, Havener VR, Cameron JD. Cellulose acetate impression of ocular surface. Dry eye states. Arch Ophthalmol. 1983;101:1869–1872.
- Coulter I, Frewin S, Krassas GE, et al. Psychological implications of Graves’ orbitopathy. Euro J Endocrinol. 2007;157:127–131.
- Pflugfelder SC, Farley W, Luo L, et al. Matrix metalloproteinase-9 knockout confers resistance to corneal epithelial barrier disruption in experimental dry eye. Am J Pathol. 2005;166:61–71.
- Luo L, Li DQ, Doshi A, et al. Experimental dry eye stimulates production of inflammatory cytokines and MMP-9 and activates MAPK signaling pathways on the ocular surface. Invest Ophthalmol Vis Sci. 2004;45:4293–4301.
- El Annan J, Chauhan SK, Ecoiffier T, et al. Characterization of effector T cells in dry eye disease. Invest Ophthalmol Vis Sci. 2009;50:3802–3807.
- Gumus K, Cavanagh DH. The role of inflammation and antiinflammation therapies in keratoconjunctivitis sicca. Clin Ophthalmol. 2009;3:57–67.
- Dias AC, Módulo CM, Jorge AG, et al. Influence of thyroid hormone on thyroid hormone receptor β-1 expression and lacrimal gland and ocular surface morphology. Invest Ophthalmol Vis Sci. 2007;48:3038–3042.
- Hoffman RA, Wertz P, Habeeb P. Harderian glands of golden hamsters: Morphological and biochemical responses to thyroid hormones. J Comp Physiol. 1989;159:293–299.
- Zeher M, Horvath IF, Szanto A, et al. Autoimmune thyroid diseases in a large group of Hungarian patients with primary Sjögren’s syndrome. Thyroid. 2009;19:39–45.
- Gupta A, Sadeghi PB, Akpek EK. Occult thyroid eye disease in patients presenting with dry eye symptoms. Am J Ophthalmol. 2009;147:919–923.
- Nunery WR, Martin RT, Heinz GW, et al. The association of cigarette smoking with clinical subtypes of ophthalmic Graves’ disease. Ophthal Plast Reconstr Surg. 1993;9:77–82.